NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

Breast Cancer Research

Table 4 Antitumor effect and tolerability of NVP-AUY922 against BT-474 tumor-bearing nude mice when administered once per week

	Tumor response		Host response
NVP-AUY922 dose, mg/kg	T/C, percentage	Tumor volume change, cubic millimeters	Body weight change, grams	Body weight change, percentage	Survival, percentage
0	100	266 ± 51	-1.6 ± 0.9	-5.9 ± 3.2	100
8.3	95	252 ± 73	-2.2 ± 0.8	-7.3 ± 2.6	100
17	72	191 ± 61	-1.2 ± 0.7	-4.8 ± 2.9	88
25	12	32 ± 15^a	-1.7 ± 0.6	-6.5 ± 2.5	100
41	3	9 ± 13^a	-2.4 ± 0.6	-9.7 ± 2.7	100
58	8	22 ± 26^a	-3.0 ± 1.2	-10.9 ± 4.2	100

BT-474 cells were inoculated subcutaneously in female nude mice carrying an estrogen-release pellet. When the tumors reached 100 to 200 mm³, drug treatment was initiated. Each group consisted of eight animals. NVP-AUY922 was administered once per week at the indicated dose levels. Tumor volumes and body weights were measured three times per week, and the experiment was evaluated 20 days after the first dose was administered. The percentage T/C represent the mean change in tumor volume of the treated group divided by the mean change in tumor volume of the vehicle treated control group. ^aStatistical significance compared with vehicle-treated controls (P < 0.05, one-way analysis of variance post hoc Dunnett).

ISSN: 1465-542X